Vying Valves: Edwards’ Sapien Progresses, But CoreValve Remains A Threat
This article was originally published in The Gray Sheet
Executive Summary
European data for Edwards Lifesciences' Sapien transcatheter heart valve are encouraging, but analysts have raised questions about design of the firm's planned U.S. trial of the device
You may also be interested in...
Heart Valve Device Approvals: FDA Issues New Draft Guidance
A single-arm clinical study with literature-based controls is typically sufficient for a PMA supporting a new open-surgery heart valve replacement device, FDA says in a draft guidance issued Jan. 20
Heart Valve Device Approvals: FDA Issues New Draft Guidance
A single-arm clinical study with literature-based controls is typically sufficient for a PMA supporting a new open-surgery heart valve replacement device, FDA says in a draft guidance issued Jan. 20
Medtronic Catapults Into Transcatheter Valve Market With Billion-Dollar Buys
Medtronic will enter the high-growth, minimally invasive aortic heart valve market through two acquisitions worth more than $1 billion